Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients - PubMed (original) (raw)
Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients
A Ghirardello et al. J Autoimmun. 2004 May.
Abstract
We prospectively analyzed the diagnostic sensitivity and specificity as well as the clinical relevance of antinucleosome antibodies in SLE. One hundred and one consecutive SLE patients were followed for 3 years. Three serial serum samples from each patient were tested for antinucleosome antibodies by ELISA (optimum cut-off value 10 U/ml), and for anti-dsDNA antibody (by ELISA and IIF on Crithidia luciliae), and anti-dsDNA avidity (by Scatchard plot analysis). Sera from 100 healthy individuals (HI), 35 patients with systemic sclerosis (SSc), 30 with primary Sjögren's syndrome (SS), 20 with rheumatoid arthritis (RA) and 48 with infectious diseases (ID), were assayed as controls. SLE activity and damage were evaluated using the ECLAM score and the SLICC/ACR index. At baseline, antinucleosome antibodies were found in 87 patients with SLE (86.1%), in 8 patients with SSc (22.8%), in 2 HI (2%), and in 1 ID (2.1%). The sensitivity and specificity of antinucleosome testing for SLE were 86.1% and 95.3%, respectively. The prevalence of antinucleosome antibodies in SLE was significantly higher than that of anti-dsDNA antibodies, with a correlation between them. No relevant relationship was found between antinucleosome antibodies and disease features, including renal involvement, disease activity, and disease damage. During follow-up, no significant variation was observed in antinucleosome level, nor in anti-dsDNA antibody level or avidity. We conclude that antinucleosome antibodies are commonly found in SLE. Low antibody levels can be detected in SSc, whereas medium/high levels are highly specific for SLE. Their clinical relevance during the disease course and utility for monitoring the individual patient seem to be poor.
Similar articles
- Antinucleosome antibodies and systemic lupus erythematosus.
Düzgün N, Sahin M, Genç Y, Tutkak H. Düzgün N, et al. Ann N Y Acad Sci. 2007 Aug;1109:421-8. doi: 10.1196/annals.1398.048. Ann N Y Acad Sci. 2007. PMID: 17785331 - Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus.
Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, Bach JF, Piette JC. Amoura Z, et al. Arthritis Rheum. 2000 Jan;43(1):76-84. doi: 10.1002/1529-0131(200001)43:1<76::AID-ANR10>3.0.CO;2-I. Arthritis Rheum. 2000. PMID: 10643702 - Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus.
Bruns A, Bläss S, Hausdorf G, Burmester GR, Hiepe F. Bruns A, et al. Arthritis Rheum. 2000 Oct;43(10):2307-15. doi: 10.1002/1529-0131(200010)43:10<2307::AID-ANR19>3.0.CO;2-J. Arthritis Rheum. 2000. PMID: 11037891 - [Role of the nucleosome in the physiopathology of systemic lupus erythematosus].
Amoura Z, Piette JC. Amoura Z, et al. Ann Med Interne (Paris). 2003 Feb;154(1):25-32. Ann Med Interne (Paris). 2003. PMID: 12746656 Review. French. - Nucleosomes in the pathogenesis of systemic lupus erythematosus.
Koutouzov S, Jeronimo AL, Campos H, Amoura Z. Koutouzov S, et al. Rheum Dis Clin North Am. 2004 Aug;30(3):529-58, ix. doi: 10.1016/j.rdc.2004.04.001. Rheum Dis Clin North Am. 2004. PMID: 15261340 Review.
Cited by
- Assessment of anti-nucleosome antibody (ANuA) isotypes for the diagnosis and prediction of systemic lupus erythematosus and lupus nephritis activity.
Zeng Y, Xiao Y, Zeng F, Jiang L, Yan S, Wang X, Lin Q, Yu L, Lu X, Zhang Y, Lin Y. Zeng Y, et al. Clin Exp Med. 2023 Sep;23(5):1677-1689. doi: 10.1007/s10238-022-00942-w. Epub 2022 Nov 16. Clin Exp Med. 2023. PMID: 36385418 - Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus.
Li T, Prokopec SD, Morrison S, Lou W, Reich H, Gladman D, Urowitz M, Scholey J, Fortin PR, Boutros PC, Wither J, Landolt-Marticorena C. Li T, et al. Rheumatology (Oxford). 2015 Mar;54(3):449-57. doi: 10.1093/rheumatology/keu326. Epub 2014 Sep 5. Rheumatology (Oxford). 2015. PMID: 25193804 Free PMC article. - Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.
Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A. Zen M, et al. Clin Rev Allergy Immunol. 2013 Oct;45(2):227-35. doi: 10.1007/s12016-013-8355-1. Clin Rev Allergy Immunol. 2013. PMID: 23322404 Review. - A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, Daha MR, Berden JH. Grootscholten C, et al. Ann Rheum Dis. 2007 May;66(5):693-6. doi: 10.1136/ard.2006.065425. Epub 2006 Nov 29. Ann Rheum Dis. 2007. PMID: 17135217 Free PMC article. Clinical Trial. - Clinical aspects and risk factors of lupus nephritis: a retrospective study of 156 adult patients.
Yuan F, Wei F, Wang J, You Y. Yuan F, et al. J Int Med Res. 2019 Oct;47(10):5070-5081. doi: 10.1177/0300060519871812. Epub 2019 Sep 12. J Int Med Res. 2019. PMID: 31510838 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical